CrmA Adenovirus
Category: Adenovirus > Over-Expression
Cat. No: 1032
Availability:
Immediate
Name:
Ad-CMV-CrmA
Cytokine response modifier A
$475.00
Request a Quote
Please enter your email address and we'll be in touch with more information:
Viral Details
- Viral Backbone
- Human Adenovirus Type5 (dE1/E3)
- Promoter
- CMV (ubiquitous)
- Storage Buffer
- DMEM, 2% BSA, 2.5% Glycerol
- Volume
- 200ul
- Titer
- 1x10^10 PFU/ml
Product Citations
This product is referenced in the following publications:
- Lee, V. etc (2005). Bleomycin induces alveolar epithelial cell death through JNK-dependent activation of the mitochondrial death pathway. American Journal of Physiology - Lung Cellular and Molecular Physiology.
- Yacoub, A. etc (2008). Caspase-, cathepsin-, and PERK-dependent regulation of MDA-7/IL-24-induced cell killing in primary human glioma cells. Molecular Cancer Therapeutics.
- Mitchell, C., etc. (2007). Low-Dose Bbr3610 Toxicity In Colon Cancer Cells Is P53-Independent And Enhanced By Inhibition Of Epidermal Growth Factor Receptor (Erbb1)-Phosphatidyl Inositol 3 Kinase Signaling. Mol Pharmacol.
- Park, M., etc. (2008). Mitogen-Activated Protein Kinase Kinase 1/2 Inhibitors And 17-Allylamino-17-Demethoxygeldanamycin Synergize To Kill Human Gastrointestinal Tumor Cells In Vitro Via Suppression Of C-Flip-S Levels And Activation Of Cd95. Molecular Cancer Therapeutics.
- Hossein A Hamed, etc (2013). Histone Deacetylase Inhibitors Interact with MDA-7/IL-24 to Kill Primary Human Glioblastoma Cells. Molecular Pharmacology.
- Yacoub, A., etc. (2008). Regulation Of Gst-Mda-7 Toxicity In Human Glioblastoma Cells By Erbb1, Erk1/2, Pi3k, And Jnk1-3 Pathway Signaling. Molecular Cancer Therapeutics.
- Zhang, G., etc. (2008). Vorinostat And Sorafenib Synergistically Kill Tumor Cells Via Flip Suppression And Cd95 Activation. Clinical Cancer Research.
- Park MA, etc (2008). Vorinostat And Sorafenib Increase Er Stress, Autophagy And Apoptosis Via Ceramide-Dependent Cd95 And Perk Activation. Cancer Biol Ther.
- Park MA, etc (2009). Mek1/2 Inhibitors And 17AAG Synergize To Kill Human Gi Tumor Cells In Vitro Via Suppression Of C-Flip-S Levels And Activation Of Cd95. Mol Cancer Ther.
- Walker T, etc (2009). Sorafenib And Vorinostat Kill Colon Cancer Cells By Cd95-Dependent And -Independent Mechanisms. Mol Pharmacol.
- Mitchell, C. etc (2007). Extrinsic Pathway- And Cathepsin-Dependent Induction Of Mitochondrial Dysfunction Are Essential For Synergistic Flavopiridol And Vorinostat Lethality In Breast Cancer Cells. Molecular Cancer Therapeutics.
- Adly Yacoub (2009). PERK-dependent regulation of ceramide synthase 6 and thioredoxin play a key role in mda-7/IL-24-induced killing of primary human glioblastoma multiforme cells. Cancer Research.
- Teneille Walker (2010). 17-Allylamino-17-Demethoxygeldanamycin and MEK1/2 Inhibitors Kill GI Tumor Cells via Ca2+-Dependent Suppression of GRP78/BiP and Induction of Ceramide and Reactive Oxygen Species. Mol Cancer Ther.
- Hossein A Hamed (2010). Inhibition of Multiple Protective Signaling Pathways and Ad. 5/3 Delivery Enhances mda-7/IL-24 Therapy of Malignant Glioma. Molecular Therapy.
- Adly Yacoub (2009). Cisplatin Enhances Protein Kinase R-Like Endoplasmic Reticulum Kinase- and CD95-Dependent Melanoma Differentiation-Associated Gene-7/Interleukin-24¿Induced Killing in Ovarian Carcinoma Cells. Molecular Pharmacology.
- Teneille Walker, ETC (2010). 17AAG and MEK1/2 inhibitors kill GI tumor cells via Ca2+-dependent suppression of GRP78/BiP and induction of ceramide and ROS. Mol Cancer Ther.
Control Products
| Product | Cat No. |
|---|---|
| Ad-CMV-Luc | 1000 |
| Ad-GFP | 1060 |
| Ad-CMV-b-Gal | 1080 |
| Ad-Null | 1240 |
| Ad-CMV-Null | 1300 |
| Ad-RFP | 1660 |
| Ad-CFP | 1766 |
| Ad-mCherry | 1767 |
Vector Biolabs
293 Great Valley Parkway
Malvern, PA 19355
Email: info@vectorbiolabs.com
Phone: +1 484-325-5100
Toll-free (US Only): 877-BIO-LABS
Fax: +1 215-525-1112
Privacy Policy